Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Australasian Guideline (2nd Edition): an Annex to the CLSI and UK Guidelines for the Performance of the Sweat Test for the Diagnosis of Cystic Fibrosis.

Massie J, Greaves R, Metz M, Wiley V, Graham P, Shepherd S, Mackay R.

Clin Biochem Rev. 2017 Nov;38(3):115-130. No abstract available.

2.

Biomarkers of inflammation in infants with cystic fibrosis.

Laguna TA, Williams CB, Nunez MG, Welchlin-Bradford C, Moen CE, Reilly CS, Wendt CH.

Respir Res. 2018 Jan 8;19(1):6. doi: 10.1186/s12931-017-0713-8.

3.

Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.

Donaldson SH, Pilewski JM, Griese M, Cooke J, Viswanathan L, Tullis E, Davies JC, Lekstrom-Himes JA, Wang LT; VX11-661-101 Study Group.

Am J Respir Crit Care Med. 2018 Jan 15;197(2):214-224. doi: 10.1164/rccm.201704-0717OC.

4.

What can the CF registry tell us about rare CFTR-mutations? A Belgian study.

De Wachter E, Thomas M, Wanyama SS, Seneca S, Malfroot A.

Orphanet J Rare Dis. 2017 Aug 22;12(1):142. doi: 10.1186/s13023-017-0694-1.

5.

Association between spirometry controlled chest CT scores using computer-animated biofeedback and clinical markers of lung disease in children with cystic fibrosis.

Kongstad T, Green K, Buchvald F, Skov M, Pressler T, Nielsen KG.

Eur Clin Respir J. 2017 May 2;4(1):1318027. doi: 10.1080/20018525.2017.1318027. eCollection 2017.

6.

Cystic fibrosis prevalence among a group of high-risk children in the main referral children hospital in Iran.

Modaresi MR, Faghinia J, Reisi M, Keivanfar M, Navaie S, Seyyedi J, Baharzade F.

J Educ Health Promot. 2017 Jun 5;6:54. doi: 10.4103/jehp.jehp_80_15. eCollection 2017.

7.

Lung structure and function similarities between primary ciliary dyskinesia and mild cystic fibrosis: a pilot study.

Maglione M, Montella S, Mollica C, Carnovale V, Iacotucci P, De Gregorio F, Tosco A, Cervasio M, Raia V, Santamaria F.

Ital J Pediatr. 2017 Apr 12;43(1):34. doi: 10.1186/s13052-017-0351-2.

8.

Intragenic CFTR Duplication and 5T/12TG Variant in a Patient with Non-Classic Cystic Fibrosis.

Celestino-Soper PB, Simpson E, Tumbleson Brink D, Lynnes TC, Dlouhy S, Vatta M, Yeley J, Brown C, Bai S.

Sci Rep. 2016 Dec 20;6:38776. doi: 10.1038/srep38776.

9.

Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR.

Milla CE, Ratjen F, Marigowda G, Liu F, Waltz D, Rosenfeld M; VX13-809-011 Part B Investigator Group * .

Am J Respir Crit Care Med. 2017 Apr 1;195(7):912-920. doi: 10.1164/rccm.201608-1754OC.

10.

A Review of Transplantation Practice of the Urologic Organs: Is It Only Achievable for the Kidney?

Donati-Bourne J, Roberts HW, Rajjoub Y, Coleman RA.

Rev Urol. 2015;17(2):69-77. doi: 10.3909/riu0659. Review.

11.

Respiratory therapy: a problem among children and adolescents with cystic fibrosis.

Feiten Tdos S, Flores JS, Farias BL, Rovedder PM, Camargo EG, Dalcin Pde T, Ziegler B.

J Bras Pneumol. 2016 Jan-Feb;42(1):29-34. doi: 10.1590/S1806-37562016000000068. English, Portuguese.

12.

Refining the continuum of CFTR-associated disorders in the era of newborn screening.

Levy H, Nugent M, Schneck K, Stachiw-Hietpas D, Laxova A, Lakser O, Rock M, Dahmer MK, Biller J, Nasr SZ, Baker M, McColley SA, Simpson P, Farrell PM.

Clin Genet. 2016 May;89(5):539-49. doi: 10.1111/cge.12711. Epub 2016 Jan 20.

13.

Burkholderia cepacia complex: clinical course in cystic fibrosis patients.

Folescu TW, da Costa CH, Cohen RW, da Conceição Neto OC, Albano RM, Marques EA.

BMC Pulm Med. 2015 Dec 8;15:158. doi: 10.1186/s12890-015-0148-2.

14.

Distribution of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations in a Cohort of Patients Residing in Palestine.

Siryani I, Jama M, Rumman N, Marzouqa H, Kannan M, Lyon E, Hindiyeh M.

PLoS One. 2015 Jul 24;10(7):e0133890. doi: 10.1371/journal.pone.0133890. eCollection 2015.

15.

Metabolomics analysis identifies novel plasma biomarkers of cystic fibrosis pulmonary exacerbation.

Laguna TA, Reilly CS, Williams CB, Welchlin C, Wendt CH.

Pediatr Pulmonol. 2015 Sep;50(9):869-77. doi: 10.1002/ppul.23225. Epub 2015 Jun 26.

16.

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.

Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M; VX11-770-110 (KONDUCT) Study Group.

Lancet Respir Med. 2015 Jul;3(7):524-33. doi: 10.1016/S2213-2600(15)00201-5. Epub 2015 Jun 9.

17.

New challenges in the diagnosis and management of cystic fibrosis.

Levy H, Farrell PM.

J Pediatr. 2015 Jun;166(6):1337-41. doi: 10.1016/j.jpeds.2015.03.042. No abstract available.

18.

Reduced bacterial colony count of anaerobic bacteria is associated with a worsening in lung clearance index and inflammation in cystic fibrosis.

O'Neill K, Bradley JM, Johnston E, McGrath S, McIlreavey L, Rowan S, Reid A, Bradbury I, Einarsson G, Elborn JS, Tunney MM.

PLoS One. 2015 May 20;10(5):e0126980. doi: 10.1371/journal.pone.0126980. eCollection 2015.

19.

Forced oscillations and respiratory system modeling in adults with cystic fibrosis.

Lima AN, Faria AC, Lopes AJ, Jansen JM, Melo PL.

Biomed Eng Online. 2015 Feb 13;14:11. doi: 10.1186/s12938-015-0007-7.

20.

The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes.

Mulrennan S, Baltic S, Aggarwal S, Wood J, Miranda A, Frost F, Kaye J, Thompson PJ.

Sci Rep. 2015 Mar 10;5:8931. doi: 10.1038/srep08931.

Supplemental Content

Support Center